Genfit (EPA:GNFT), (NASDAQ:GNFT) is a biopharmaceutical company dedicated to the discovery and development of innovative treatment solutions for liver diseases and other chronic conditions. Focused primarily on advancing therapeutic and diagnostic approaches, its projects include developing elafibranor for non-alcoholic steatohepatitis (NASH) and a diagnostic test for the early detection of liver disease complications. Genfit is committed to addressing unmet medical needs by bringing novel drugs and technologies to patients worldwide, aiming to improve patient outcomes and quality of life in areas with significant therapeutic gaps.